5 things you missed as Greg Brockman took the stand at the OpenAI trial

Greg Brockman testified that he owns nearly $30 billion in OpenAI shares and $471 million in Stripe shares, placing him among the world's richest people. He also confirmed OpenAI is exploring an IPO, which would be among the largest ever given its reported $850 billion private valuation. The trial also revealed Elon Musk's $5,000/hour expert witness compensation and settlement outreach to Brockman two days before proceedings resumed.

Analysis

The market is underpricing how much this trial is really about control rights and founder credibility, not just historical charity language. If the court broadens discovery into OpenAI’s governance and financing roadmap, the biggest near-term beneficiary is every credible AI competitor and infrastructure name that can market itself as a cleaner, less litigious alternative to capital allocators. The second-order effect is on private-market pricing: a validated path to IPO for a frontier model lab would re-anchor late-stage AI valuation comps, but it also invites a much higher public-market discount rate because investors will finally be able to scrutinize governance, dilution, and related-party complexity in real time.

The IPO signal matters less as a binary event than as an optionality unlock. Even acknowledging an IPO could pull forward expectations for a listing window over the next 12-24 months, but it also raises the probability of a more conservative cap table structure, employee retention pressure, and tighter disclosure around compute commitments and customer concentration. That combination tends to compress multiple expansion in the private rounds that come before the listing, especially for peers whose only differentiation is headline model scale rather than durable distribution or enterprise integration.

The more interesting risk is that litigation becomes a forcing function for rival narratives: if public testimony keeps emphasizing wealth concentration and governance ambiguity, regulators and enterprise buyers may increasingly favor “enterprise-first” AI vendors with clearer control structures. Over a 3-6 month horizon, that is a relative positive for the picks-and-shovels ecosystem and a modest negative for the most richly priced frontier-model beneficiaries if they are perceived as harder to diligence. The contrarian view is that the spectacle itself can be bullish by normalizing OpenAI as a public-company-style asset and making an eventual IPO feel inevitable rather than optional.

Key Decisions for Investors

• Long MSFT vs. short a basket of late-stage private AI names via proxies where available (or offsetting exposure in AI venture funds): 3-6 month horizon. Thesis: governance scrutiny and IPO optionality favor the best-distributed platform while compressing private-mark multiple expansion.
• Initiate a relative-value long on AI infrastructure beneficiaries (NVDA, ANET, SMCI) vs. frontier-model purity trades over 1-2 quarters. Thesis: regardless of litigation outcome, compute demand and disclosure pressure should keep capex flowing to picks-and-shovels.
• Buy medium-dated call spreads on MSFT into any trial-driven weakness over the next 2-8 weeks. Risk/reward: limited premium outlay for exposure to the market’s most credible AI monetization stack if OpenAI governance noise drives a transient selloff.
• Avoid chasing freshly marked private AI valuations for the next 1-2 fundraising cycles. Thesis: if IPO chatter hardens, later-stage rounds will need to clear a higher governance discount, not a higher enthusiasm multiple.